TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from KYORIN Pharmaceutical Co.,Ltd. ( (JP:4569) ).
KYORIN Pharmaceutical Co., Ltd. announced the topline results from a Phase 3 clinical study of KRP-R120 (Efzofitimod) for treating pulmonary sarcoidosis. The study did not meet its primary endpoint but showed some promising secondary outcomes, such as a higher rate of complete steroid withdrawal in patients treated with KRP-R120 compared to placebo. The drug was well-tolerated, and the results will be presented at the European Respiratory Society Congress. KYORIN and aTyr Pharma are discussing future development plans for KRP-R120, and the study costs have been included in the company’s financial forecasts.
The most recent analyst rating on (JP:4569) stock is a Buy with a Yen1706.00 price target. To see the full list of analyst forecasts on KYORIN Pharmaceutical Co.,Ltd. stock, see the JP:4569 Stock Forecast page.
More about KYORIN Pharmaceutical Co.,Ltd.
KYORIN Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and distribution of innovative drugs. The company is engaged in the research and development of treatments for various diseases, with a particular emphasis on respiratory and infectious diseases.
Average Trading Volume: 86,914
Technical Sentiment Signal: Buy
Current Market Cap: Yen82.38B
See more insights into 4569 stock on TipRanks’ Stock Analysis page.